Clinical trials: Cell Transplantation
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Patients receiving allogeneic stem cell transplantation for hematological malignancies who suffer a relapse of their disease post-transplant have limited treatment options and a poor prognosis.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic
- Trial name
- NCT00859586
- Testing
- Miltenyi Magnetic cell sorter for CD3
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia.
- Conditions
- Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT00563290
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lung Injury
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute lung injury (ALI) is a common, life-threatening complication among pediatric leukemia and lymphoma and hematopoietic stem cell transplant (HSCT) recipients.
- Trial name
- CALIPSO (NCT00999713)
- Testing
- Calfactant
- Where
- 16 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Milton S. Hershey Medical Center
Multiple Myeloma
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding…
- Trial name
- NCT01548573
- Testing
- Dexamethasone, Tandem autologous stem cell transplant, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Iowa
Cytomegalovirus (CMV) Infection
Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to <18 years of age…
- Trial name
- NCT03940586
- Testing
- Letermovir oral granules, Letermovir tablet, Letermovir intravenous
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Amenorrhea, Premature Ovarian Failure
GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Primary Objectives: To determine the effectiveness of the 3-month depot leuprolide in inducing and maintaining secondary amenorrhea in patients undergo hematopoietic stem cell transplantation.
- Conditions
- Amenorrhea, Premature Ovarian Failure, Ovarian Function Insufficiency
- Trial name
- NCT00429494
- Testing
- Leuprolide Acetate, Questionnaire, Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasm Metastasis
Stem Cell Transplantation for Metastatic Solid Tumors
The goal of this research study is to identify other types of cancer (malignant neoplasms) that may be treatable with stem cell transplantation (allogenic peripheral blood stem cell transplantation.
- Trial name
- NCT00001880
- Testing
- methotrexate, Cyclosporin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called…
- Trial name
- NCT00588094
- Testing
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sickle Cell Disease
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD).
- Trial name
- NCT03263559
- Testing
- Haploidentical Bone Marrow Transplantation, Hydroxyurea, Rabbit-ATG
- Where
- 32 sites in United States
- Volunteers
- 95 people
- Sponsor
- Medical College of Wisconsin
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells and prepares the patient's…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis
- Trial name
- NCT00309842
- Testing
- filgrastim, cyclophosphamide, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 213 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Malignancy, Myeloid Malignancy
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.
- Trial name
- NCT05579769
- Testing
- Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia, Leukemia, Lymphoblastic, Acute
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers
This study is to evaluate the safety of transplantation of two cord blood products, including toxicities in patients following high-dose, myeloablative chemotherapy for blood malignancies.
- Conditions
- Acute Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Leukemia, Bilineage, Acute, Leukemia, Myeloid, Chronic
- Trial name
- Cord Blood (NCT00539656)
- Testing
- Ex vivo expansion of cord blood
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
This phase II trial studies the side effects and best dose of bortezomib when given with chemotherapy and to see how well they work in treating participants with lymphoid malignancies undergoing stem cell transplant.
- Conditions
- CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
- Trial name
- NCT00439556
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Malignancies, Acute Myelogenous Leukemia
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation.
- Conditions
- Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Disorders
- Trial name
- FLUBUTBI (NCT01366612)
- Testing
- Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
This study will examine whether 240 µg/kg plerixafor given alone for up to 4 days is safe and well tolerated in multiple myeloma (MM) patients.
- Trial name
- NCT00396383
- Testing
- plerixafor
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Genzyme, a Sanofi Company
Mantle Cell Lymphoma
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating…
- Trial name
- NCT04626791
- Testing
- Acalabrutinib, Bortezomib, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Academic and Community Cancer Research United
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.